For example, myocarditis, one of the most severe immune checkpoint inhibitor-related toxicities, has been documented in cases where patients receiving anti-PD-1 therapies, such as pembrolizumab and nivolumab, developed fatal myocarditis, resulting in cardiac arrest in some instances. The gene discussed is PDCD1; the disease is myocarditis.